Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial health with $332 million cash and $8.2 billion in potential milestone payments. Key partnerships and promising gene therapy developments indicate positive business momentum. The Q&A section reveals optimism about upcoming milestones and external partnerships, despite some management ambiguity. Overall, the financial outlook and strategic advancements suggest a positive stock price movement.
Key Financial Performance
Cash $332 million, an increase from the previous year, attributed to significant non-dilutive revenue from partnerships and potential future milestone payments of $8.2 billion.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VY1706: VY1706, our tau silencing gene therapy, has moved forward into IND-enabling studies and is advancing toward IND in 2026.
VY7523: Our anti-tau antibody, VY7523, performed well in a recently completed single ascending dose study, with no serious adverse events.
Partnerships: Voyager has partnerships that have generated significant non-dilutive revenue, with $332 million in cash and $8.2 billion in potential future milestone payments.
SOD1 Program: The SOD1 silencing gene therapy program has moved back into the research stage due to the payload not meeting target profiles.
Non-Human Primate Studies: Data from three-month non-human primate studies for VY1706 showed 50% to 73% knockdown of tau messenger RNA across the brain.
Gene Therapy Approach: Voyager emphasizes IV delivery of gene therapies as critical for commercial viability, differentiating its approach from the broader gene therapy field.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Issues: The company acknowledges that their forward-looking statements are subject to risks and uncertainties, which may affect actual results. This includes regulatory challenges that could impact the approval and commercialization of their gene therapy products.
Competitive Pressures: Voyager Therapeutics faces competitive pressures in the gene therapy field, particularly as they highlight the importance of differentiating their approach from others in the industry. The mention of Zolgensma's success indicates the competitive landscape they are navigating.
Supply Chain Challenges: The company did not explicitly mention supply chain challenges, but the need to identify a new payload for their SOD1 silencing gene therapy program suggests potential supply chain or development hurdles.
Economic Factors: The company has $332 million in cash and $8.2 billion in potential future milestone payments, indicating a reliance on partnerships for financial stability, which could be affected by broader economic conditions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Pipeline Development: Voyager has four wholly owned and 13 partnered programs, with a focus on two wholly owned programs targeting tau in Alzheimer's disease.
Partnerships: Voyager has generated significant non-dilutive revenue through partnerships, reporting $332 million in cash and $8.2 billion in potential future milestone payments.
Gene Therapy Approach: Voyager emphasizes the importance of IV delivery and genetically validated targets in severe diseases, differentiating its approach from broader gene therapy trends.
VY1706 Progress: VY1706, a tau silencing gene therapy, has advanced into IND-enabling studies and is expected to reach IND by 2026.
VY7523 Development: The anti-tau antibody VY7523 has shown promising results in a single ascending dose study and is moving into a multiple ascending dose study.
Future Milestones: Voyager anticipates sharing more data on VY1706 at the ADPD conference in April and expects initial tau PET data for VY7523 in the second half of 2026.
Financial Outlook: The company expects partnerships to continue contributing significantly to its bottom line, with a focus on additional business opportunities.
Research and Development: The SOD1 silencing gene therapy program has moved back into research due to unmet target profile, indicating ongoing adjustments in R&D strategy.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide additional color ahead of ADPD regarding external readouts in the tau space?
A:At ADPD, I hope to see data from bepranemab on exposure PD relationship and more data on tau spreading decrease needed for clinically relevant effects. Also, information on subgroups with greater efficacy, such as APOE4 carrier status.
Q:What are your thoughts on upcoming milestones from Neurocrine or additional external partnerships?
A:There are $2.9 billion of developmental milestones, which are not included in our guidance, representing additional upside to our mid-2027 cash runway guidance.
Q:Can you provide details on what needs to be completed before the tau gene silencing IND can be filed next year?
A:We need to complete the GLP tox study and ensure we have a therapeutic window without safety issues.
Q:What indications are you considering for the ALPL shuttle?
A:We're looking broadly across various diseases, including spinal cord and cerebral cortex diseases, and assessing the transport of proteins, antibodies, and oligonucleotides.
Q:What are the key differences expected between tau silencing and targeting antibodies?
A:The knockdown approach allows for better bio-distribution and broader tau knockdown compared to intrathecal injections of antibodies.
Q:What are the key differences between the two approaches for tau in preclinical studies?
A:Both approaches show positive results, but the knockdown approach may reduce the amount of tau and impede its spread.
Q:What is the expected target level of tau mRNA knockdown?
A:We're targeting a knockdown range of 50% to 73%.
Q:What are the limitations of TfR-based brain shuttles?
A:TfR-based shuttles may lead to hematologic adverse events due to their function, while ALPL may be more tolerable.
Q:What key results would lead to a decision on the anti-tau antibody program?
A:I would look for a significant effect on tau spreading and a clinically meaningful effect on CDR sum of boxes.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding specific upcoming milestones from Neurocrine and the exact nature of the preclinical data set for the non-viral shuttle. Additionally, there was a lack of clarity on the specific differences between the Merck antibody and their own antibody.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Affairs Officer
Allen Baird
Baird Phil
CEO Alfred
Canaccord Genuity
Cantor Fitzgerald
Chief Corporate
Chief Medical
Co Patrick
Co afternoon
Corporate Affairs
Cowen Pete
Dr Chief
ET Jay
End Financial
Fitzgerald Lili
Genuity Conference
Jack Allen
Jay Olson
Kulkarni Canaccord
Lili Nsongo
Medical Officer
Nsongo Leerink
Officer Chief
Officer Dr
Officer Jack
Officer Voyager
Officer milestone
Partners Mehdi
Patrick Trucchio
Pete Stavropoulos
Phil Nadeau
QA
VYGR Transcript
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Neutral3-3
Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript
Neutral9-2
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2024 Earnings Call Transcript
Unknown3-12
The earnings call revealed missed EPS expectations, indicating financial instability. Despite promising partnerships and clinical milestones, setbacks in gene therapy and reliance on partnerships pose risks. Regulatory challenges and market competition further add to uncertainties. The Q&A highlighted management's evasive responses and potential risks in clinical trials. Overall, the negative sentiment from financial results and uncertainties outweighs the positives, suggesting a negative stock price reaction.
Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript
Positive3-11
The earnings call highlights strong financial health with $332 million cash and $8.2 billion in potential milestone payments. Key partnerships and promising gene therapy developments indicate positive business momentum. The Q&A section reveals optimism about upcoming milestones and external partnerships, despite some management ambiguity. Overall, the financial outlook and strategic advancements suggest a positive stock price movement.
VYGR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
